Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 4

Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results

Authors Marco Metra, Savina Nodari, Tania Bordonali, Patrizia Milani, Carlo Lombardi, et al

Published 15 September 2007 Volume 2007:3(4) Pages 569—578

Marco Metra, Savina Nodari, Tania Bordonali, Patrizia Milani, Carlo Lombardi, Silvia Bugatti, Benedetta Fontanella, Giulia Verzura, Rossella Danesi, Livio Dei Cas

Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy

Abstract: Clinical trials have consistently shown the benefits of beta-blocker treatment in patients with chronic heart failure (HF). As a result, bisoprolol, carvedilol, and metoprolol succinate are now indicated for the treatment of all patients with chronic HF who do not have major contraindications. Bisoprolol is the first beta-blocker shown to improve survival in an outcome trial. In the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), all-cause mortality and sudden death were reduced in patients treated with bisoprolol compared with those on placebo (11.8% vs 17.3%; p < 0.0001 and 3.6% vs 6.3%, p < 0.002; respectively) regardless of age, NYHA functional class, and co-morbidities. Further studies have shown both the efficacy of bisoprolol on secondary endpoints and patients subgroups as well its high cost effectiveness. More recently, CIBIS-III has shown similar efficacy and safety of the initiation of HF treatment with either bisoprolol or enalapril, with a tendency to a survival advantage with bisoprolol. Nowadays, the role of bisoprolol, as well as that of carvedilol and metoprolol succinate, in HF treatment is firmly established and research is mainly focused on implementation of treatment and better dosing. This article will summarize evidence for the efficacy of bisoprolol in the treatment of HF.

Keywords: bisoprolol, heart failure, beta-blockers

Download Article [PDF] 

Readers of this article also read:

Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD

Yvette RBM van Gestel, Sanne E Hoeks, Don D Sin, Henk Stam, Frans W Mertens, Jeroen J Bax, Ron T van Domburg, Don Poldermans

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:177-183

Published Date: 8 May 2009

Tiotropium and exercise training in COPD patients: Effects on dyspnea and exercise tolerance

Nicolino Ambrosino, Katia Foglio, Gianni Balzano, Pier Luigi Paggiaro, Patrizia Lessi, Steven Kesten

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:771-780

Published Date: 5 December 2008

A thyrotoxicosis outbreak due to dietary pills in Paris

Vincent Ioos, Vincent Das, Eric Maury, Jean-Luc Baudel, Jérôme Guéchot, et al

Therapeutics and Clinical Risk Management 2008, 4:1375-1379

Published Date: 5 December 2008

Magnetic nanoparticles for gene and drug delivery

Stuart C McBain, Humphrey HP Yiu, Jon Dobson

International Journal of Nanomedicine 2008, 3:169-180

Published Date: 6 June 2008

Developments in the management of autosomal dominant polycystic kidney disease

Amirali Masoumi, Berenice Reed-Gitomer, Catherine Kelleher, Mir Reza Bekheirnia, Robert W Schrier

Therapeutics and Clinical Risk Management 2008, 4:393-407

Published Date: 11 April 2008

Osteoporosis in the aging male: Treatment options

Stephen P Tuck, Harish K Datta

Clinical Interventions in Aging 2007, 2:521-536

Published Date: 15 January 2008

Higher persistence with valsartan compared with enalapril in daily practice

Satu J Siiskonen, Nancy S Breekveldt-Postma, Gábor Vincze, Zeba M Khan, Joëlle A Erkens, et al

Vascular Health and Risk Management 2007, 3:1039-1044

Published Date: 15 January 2008

Venlafaxine in the treatment of panic disorder

Martin A Katzman, Leslie Jacobs

Neuropsychiatric Disease and Treatment 2007, 3:59-67

Published Date: 15 March 2007

Voriconazole in the management of nosocomial invasive fungal infections

Javier Pemán, Miguel Salavert, Emilia Cantón, Isidro Jarque, Eva Romá, et al

Therapeutics and Clinical Risk Management 2006, 2:129-158

Published Date: 15 June 2006